Livongo's IPO anniversary. DTx pipelines.

Issue 062.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about two UnitedHealth acquisitions, Bristol Myers Squibb's DTx timeline, and UHG's multiple mulligans in digital diabetes. Here's what's happening this week:

HHS re-re-confirmed yesterday that we are still in a public health emergency because of COVID--19, and this third declaration will also stay in effect for at least yet another 90 days.
Bristol Myers Squibb emailed me last week after the newsletter went out. They asked me to remove the launch timeline for their multiple myeloma digital therapeutic. I found that timeline (Q3 2020 launch) on a (somewhat) blinded job posting for the project, while similar job postings explicitly from BMS didn't provide as many details. BMS said their recruiting firm made a mistake and posted an inaccurate timeline, but wouldn't share the

Sign-up for the newsletter for access.

It's a good one, too.

This article is for Exits & Outcomes subscribers only. Subscribe now to get the weekly newsletter. Enter your email below to subscribe today!

Newsletters

Livongo’s IPO anniversary. DTx pipelines.

Welcome to E&O.

Sign-up for the newsletter for access.

E&O's weekly newsletter.